Structural insights into calcium-bound S100P and the V domain of the RAGE complex.

The S100P protein is a member of the S100 family of calcium-binding proteins and possesses both intracellular and extracellular functions. Extracellular S100P binds to the cell surface receptor for advanced glycation end products (RAGE) and activates its downstream signaling cascade to meditate tumo...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Srinivasa R Penumutchu, Ruey-Hwang Chou, Chin Yu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25084534/?tool=EBI

Similar Items

S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain
by: Deepu Dowarha, et al.
Published: (2018-08-01)

S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain.
by: Md Imran Khan, et al.
Published: (2018-01-01)

Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain.
by: Md Imran Khan, et al.
Published: (2019-01-01)

The Anti-Cancer Activity of Pentamidine and Its Derivatives (WLC-4059) Is through Blocking the Interaction between S100A1 and RAGE V Domain
by: Nuzhat Parveen, et al.
Published: (2022-12-01)

Blocking the interaction between S100A9 protein and RAGE V domain using S100A12 protein.
by: Revansiddha Katte, et al.
Published: (2018-01-01)

S100P Interacts with p53 while Pentamidine Inhibits This Interaction
by: Revansiddha H. Katte, et al.
Published: (2021-04-01)

The Mouse-Specific Splice Variant mRAGE_v4 Encodes a Membrane-Bound RAGE That Is Resistant to Shedding and Does Not Contribute to the Production of Soluble RAGE.
by: Stefania Di Maggio, et al.
Published: (2016-01-01)

Amlexanox Blocks the Interaction between S100A4 and Epidermal Growth Factor and Inhibits Cell Proliferation.
by: Ching Chang Cho, et al.
Published: (2016-01-01)

Intracellular Protein S-Nitrosylation—A Cells Response to Extracellular S100B and RAGE Receptor
by: Monika Zaręba-Kozioł, et al.
Published: (2022-04-01)

Human S100A8 and S100A9 activate phagocytes via Toll-like receptor 4 independent of RAGE
by: Roth J, et al.
Published: (2009-02-01)

HMGB1-RAGE signaling pathway in pPROM
by: Huan Yan, et al.
Published: (2018-04-01)

HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets
by: Petra Tesarova, et al.
Published: (2016-03-01)

MMP-8 deficiency increases TLR/RAGE ligands S100A8 and S100A9 and exacerbates lung inflammation during endotoxemia.
by: Adrián González-López, et al.
Published: (2012-01-01)

The language of rage
by: Alison Peirse
Published: (2024-01-01)

The Ser82 RAGE Variant Affects Lung Function and Serum RAGE in Smokers and sRAGE Production In Vitro.
by: Suzanne Miller, et al.
Published: (2016-01-01)

Heparan sulfate-dependent RAGE oligomerization is indispensable for pathophysiological functions of RAGE
by: Miaomiao Li, et al.
Published: (2022-02-01)

Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P
by: Dan Zhang, et al.
Published: (2020-09-01)

RAGE and tobacco smoke: Insights into modeling chronic obstructive pulmonary disease.
by: Adam B. Robinson, et al.
Published: (2012-07-01)

Kun ope ragee
by: Anni Piironen, et al.
Published: (2025-10-01)

The Rage of Ivan Karamazov
by: Edin Pobrić
Published: (2020-01-01)

The War on Cancer Rages On
by: Alnawaz Rehemtulla
Published: (2009-12-01)

Ocular 'Roid Rage
by: Henrietta Ho MBBS, et al.
Published: (2012-03-01)

Rage beneath the machine
by: Christopher T. Burris, et al.
Published: (2025-10-01)

Obesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?
by: Chinedum Eleazu, et al.
Published: (2019-06-01)

RNP interfaces as regulatory “active sites”: a repurposing strategy for small molecules targeting viral 5′-untranslated regions
by: Louis G. Smith, et al.
Published: (2026-05-01)

Crotonylation deficiency of S100A7 K49 promotes psoriatic keratinocyte proliferation through enhanced interaction with RAGE
by: Huifang Liang, et al.
Published: (2025-04-01)

Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
by: Pratyusha Ghanta, et al.
Published: (2026-04-01)

Solvability for a fractional p-Laplacian equation in a bounded domain
by: Zhiwei Lv, et al.
Published: (2022-05-01)

Corrigendum: Obesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?
by: Chinedum Eleazu, et al.
Published: (2019-08-01)

Continuous and Lp estimates for the complex Monge-Ampère equation on bounded domains in ℂn
by: Patrick W. Darko
Published: (2002-01-01)

Polymorphisms −374 T/A and −429 T/C of the Receptor for Advanced Glycation End-Products (RAGE) and Serum Levels of RAGE (sRAGE) Are Not Associated with Metabolic Syndrome
by: Diana Elizabeth González-Guerrero, et al.
Published: (2023-04-01)

Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis.
by: Wen Wei, et al.
Published: (2012-01-01)

Raging at imaginary Don-Quixotes
by: David Tyfield
Published: (2009-09-01)

RAGE Inhibitors in Neurodegenerative Diseases
by: V. Prakash Reddy, et al.
Published: (2023-04-01)

I would like to rage
by: Chloé Galibert-Laîné
Published: (2024-01-01)

Forms of rage in Franco's Spain
by: Lisa DiGiovanni
Published: (2024-01-01)

The role of RAGE in the diabetic neuropathy
by: Judyta K. Juranek, et al.
Published: (2015-12-01)

RAGE in the pathophysiology of skeletal muscle
by: Francesca Riuzzi, et al.
Published: (2018-12-01)

Hand-ling ‘road rage’
by: Mike Lloyd, et al.
Published: (2021-08-01)

In situ controlled heteroepitaxy of single-domain GaP on As-modified Si(100)
by: Oliver Supplie, et al.
Published: (2015-12-01)